These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29432671)

  • 1. What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?
    Rawson N
    J Popul Ther Clin Pharmacol; 2017 Dec; 24(3):90-98. PubMed ID: 29432671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 6. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
    Janzen RW; Ludwig WD;
    Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis.
    Miregwa BN; Holbrook A; Law MR; Lavis JN; Thabane L; Dolovich L; Wilson MG
    CMAJ Open; 2022; 10(3):E848-E855. PubMed ID: 36167420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medication: 15 years 'EU-directive orphan drugs'].
    Dooms M
    Bull Cercle Benelux Hist Pharm; 2015 Mar; (128):21-6. PubMed ID: 26137669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies.
    Sketris IS; Metge C; Shevchuk Y; Comeau DG; Kephart GC; Blackburn J; MacCara M; Laturnas A
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):24-35. PubMed ID: 15555476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.